Hepatocyte growth factor (HGF) is one of the most potent survival-promoting factors for motor neurons. We showed that introduction of the HGF gene into neurons of G93A transgenic mice attenuates motor neuron degeneration and increases the lifespan of these mice. Currently, treatment regimens using recombinant protein are closer to clinical application than gene therapy. To examine its protective effect on motor neurons and therapeutic potential we administered human recombinant HGF (hrHGF) by continuous intrathecal delivery to G93A transgenic rats at doses of 40 or 200 Kg and 200 Kg at 100 days of age (the age at which pathologic changes of the spinal cord appear, but animals show no clinical weakness) and at 115 days (onset of paralysis), respectively, for 4 weeks each. Intrathecal administration of hrHGF attenuates motor neuron degeneration and prolonged the duration of the disease by 63%, even with administration from the onset of paralysis. Our results indicated the therapeutic efficacy of continuous intrathecal administration of hrHGF in transgenic rats and should lead to the consideration for further clinical trials in amyotrophic lateral sclerosis using continuous intrathecal administration of hrHGF.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by selective motor neuron death (1) . Approximately 10% of cases of ALS are inherited, usually as an autosomal dominant trait (2) . In~25% of familial cases, the disease is caused by mutations in the gene encoding cytosolic copper-zinc superoxide dismutase (SOD1) (3Y5). The cause of ALS is still unclear, and clinical trials have as yet failed to identify any truly effective therapeutic regimens for ALS, with only riluzole providing a modest improvement in survival. Various substances have been shown to have therapeutic effects in a murine model of ALS. However, there have been a few reports of prolongation of survival with treatment starting around the time of disease onset (6Y12).
We (13) and another group (14) developed a rat model of ALS expressing a human SOD1 transgene with 2 ALSassociated mutations: glycine to alanine at position 93 (G93A) and histidine to arginine at position 46 (H46R) (3, 5) . Similar to its murine counterpart, this rat transgenic (Tg) ALS model reproduces the major phenotypic features of human ALS. Some experimental manipulations are difficult in Tg mice because of size limitations; however, this Tg rat model allows routine implantation of infusion pumps for intrathecal drug delivery. Intrathecal drug application is a well-established method for therapy and has been used in clinical trials in patients with ALS (15) . This route of administration bypasses the blood-brain barrier, allowing rapid access to potential binding sites for the test compound in the spinal cord (16) .
Hepatocyte growth factor (HGF) was first identified as a potent mitogen for mature hepatocytes and was first cloned in 1989 (17) . Detailed studies indicated that HGF is expressed in the CNS (18) and is a novel neurotrophic factor (19, 20) . HGF is one of the most potent survivalpromoting factors for motor neurons, comparable to glial cell line-derived neurotrophic factor in vitro (21) . Sun et al (22) reported that introduction of the HGF gene into neurons of G93A Tg mice attenuates motor neuron degeneration and increases the lifespan of these mice. Thus, HGF is a good candidate agent for treatment of ALS. Currently, treatment using recombinant protein is closer to clinical application than gene therapy. However, HGF has a very 7 Copyright @ 200 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
short half-life (23Y25) and shows poor penetration into the CNS. Therefore, we examined the effects of continuous intrathecal delivery of human recombinant HGF (hrHGF) into Tg rats using implanted infusion pumps for selective and less invasive supply of HGF to the spinal cord.
MATERIALS AND METHODS

Animal Preparation and Clinical Evaluation
G93A Tg rats were genotyped by polymerase chain reaction (PCR) assay using DNA obtained from the tail as described (13) . To examine the dose and effects of hrHGF on disease onset, we began administration of 40 or 200 Kg of hrHGF (provided by H. Funakoshi and T. Nakamura, Osaka University, Osaka, Japan) or vehicle (0.1 M sulfoxide PBS) for 4 weeks to groups of eight 100-day-old Tg rats, when the pathologic changes of the spinal cord appeared, but the animals did not show weakness. All animals were killed at 130 days by deep anesthesia, and the spinal cords were examined. Because treatment of patients with ALS patients is initiated only after diagnosis based on clinical signs and symptoms, we tested the effects of hrHGF on survival with administration beginning at around the age of onset of paralysis. We administered 200 Kg of hrHGF or vehicle alone to groups of eight 115-day-old G93A Tg rats for 4 weeks, and the animals were observed until their death. To analyze the mechanism of action of hrHGF administration beginning at onset of paralysis we treated groups of six 115-day-old G93A Tg rats with 100 Kg of hrHGF or with vehicle alone for 2 weeks (a dose comparable to 200 Kg for 4 weeks). All rats were killed 2 weeks after commencement of administration of hrHGF, and their lumbar spinal cords were examined. Further groups of 3 G93A Tg rats and 3 non-Tg rats at 70, 100, and 130 days were used to measure the levels of rat HGF and c-Met. All rats were handled according to approved animal protocols of our institution and had free access to food and water throughout the experimental period and before and after pump implantation.
The onset of ALS was scored as the first observation of abnormal gait, evidence of limb weakness, or loss of extension of the hindlimbs when picked up at the base of the tail. We defined the appearance of paralysis as disease onset, although this is not a sensitive indicator and appears later than the decrease in activity (10) . However, the appearance of paralysis is a suitable marker of disease onset because it is closer to the state at which patients will be diagnosed with the disease.
Footprints were collected every 3 days by letting the rats walk on a straight path after dipping their hind paws in black ink. We measured 3 strides within the area showing regular gait and calculated the means. Footprint measurements were made for rats that began treatment at 115 days. Examiners were blinded to which group each of the rats belonged in.
Preparation of the Osmotic Pumps and Transplant Surgery
Osmotic pumps (model number 2004 or 2002; Durect Corporation, Cupertino, CA) were incubated in sterile saline at 37-C for 40 hours to attain a constant flow rate before use. Pumps were filled to capacity with hrHGF solution or vehicle using a filling needle. An infusion tube was made by connecting a 1-cm length of polyethylene tubing (PE 60; Becton Dickinson, Franklin Lakes, NJ) to a small caliber tube 9 cm in length (PE 10; Becton Dickinson) using an adhesive (ARON ALPHA; Konishi Co., Osaka, Japan). The end of the infusion tube was connected to the shorter end of the flow moderator, the longer end of which was inserted into the pump.
Surgery for placement of the pump and intrathecal administration was performed as follows. Tg rats were anesthetized using diethyl ether and 1% halothane in a mixture of 30% oxygen and 70% nitrous oxide. The skin over the third to fifth lumbar spinal process was incised and the paravertebral muscles were separated from the vertebral lamina with scissors. The fifth lumbar vertebra was laminectomized, and the dura mater was exposed for insertion of the infusion tube. Particular care was taken not to injure the dura mater during laminectomy. A small hole was bored through the dura mater with a 24-gauge needle, and a polyethylene tube (PE 10, Becton Dickinson) was inserted into the subarachnoid space approximately 3 cm rostrally. A subcutaneous pocket was made into which the osmotic pump and pump side tube were implanted. The infusion tube was attached to the fascia over the paravertebral muscles at the incision margin with silk string. A drop of adhesive (ARON ALPHA) was applied, and the incision was closed by suturing the muscles and skin.
Measurement of Rat and Human HGF in the Lumbar Spinal Cord
Slices of the fifth lumbar cord from 3 G93A Tg rats and 3 non-Tg rats at 70, 100, and 130 days as well as from 130-day-old G93A Tg rats treated with 40 or 200 Kg of hrHGF or vehicle alone for 4 weeks starting at 100 days were homogenized in buffer (20 mM Tris-HCl, pH 7.5, 0.1% Tween-80, 1 mM phenylmethylsulfonyl fluoride, and 1 mM EDTA) and centrifuged at 15,000 rpm for 30 minutes. Supernatants were separated and the concentrations of rat endogenous HGF were measured using an enzyme-linked immunosorbent assay (ELISA) kit, which is specific for rat HGF without detecting human HGF (22) (Institute of Immunology, Tokyo, Japan). For measurement of human HGF in the treated rats we used a human HGF-specific ELISA kit (IMMUNIS, Institute of Immunology), which is not reactive with rat HGF (26, 27) .
Measurement of c-Met mRNA in the Lumbar Spinal Cord of Tg Rats
Aliquots of 1 Kg of total RNA from the lumbar cords of rats were used as templates for synthesis of double- An ABI Prism 7700 Sequence Detection System (Applied Biosystems Perkin-Elmer, Foster City, CA) was used to monitor emission intensities using the above primer pairs and TaqMan fluorogenic probes. The c-Met mRNA level of G93A Tg rats relative to non-Tg rats was calculated using the Comparative C T Method (Applied Biosystems). 
Histopathologic and Immunohistochemical Analyses
To examine the dose and effects of hrHGF against disease onset, we began administration of 40 or 200 Kg of hrHGF or vehicle alone to groups of eight 100-day-old Tg rats each for 4 weeks. At 130 days, G93A Tg rats were administered hrHGF or vehicle, and non-Tg rats were deeply anesthetized with diethyl ether and killed for histopathologic evaluation. To examine the effects of hrHGF administration beginning at onset of paralysis, 100 Kg of HGF or vehicle alone was administered to groups of six 115-day-old Tg rats for 2 weeks. These animals were killed by deep anesthesia with diethyl ether 2 weeks after the operation. Under deep anesthesia these animals were perfused via the aorta with physiologic saline at 37-C and their lumbar spinal cords were removed. The fifth lumbar spinal cord tissue was embedded in OCT compound (Sakura Finetek Japan Co., Tokyo, Japan), frozen in an acetone/dry ice bath after fixation with 4% paraformaldehyde, and supplemented with 0.1 M cacodylate buffer (pH 7.3) containing 30% sucrose. Other spinal cord tissue specimens were frozen in dry ice and cut into frozen sections (12-Km-thick) and then washed with PBS. To evaluate the effects of HGF on motor neuron loss we compared the numbers of lumbar motor neurons in each group by counting as mentioned below. To evaluate the effects of HGF on apoptosis and to determine whether HGF receptors were activated, we compared the results of immunohistochemical staining of the lumbar cords for activated caspase-3, activated caspase-9 (Cell Signaling Technology, Inc., Beverly, MA), and phosphorylated c-Met (activated HGF receptor) (BioSource International, Camerillo, CA). The staining specificity of the antibodies was assessed by preabsorption of the primary antibody with excess peptide, omission of the primary antibody, or replacement of the primary antibody with normal rabbit IgG (22) . We examined every seventh section from 42 serial sections of the fifth lumbar spinal cord. We counted neurons that had a clear nucleolus and were multipolar with neuronal morphology (13, 22) , >40 Km in diameter, and located in a defined area of the anterior horn of the spinal cord. Cell counts were performed using ImageJ software (National Institutes of Health, Bethesda, MD) on images captured electronically (28) .
Western Blotting
Lysates from the lumbar spinal cord of each rat were prepared in RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, and 50 mM Tris, pH 8.0). Equal amounts of proteins from the lysates (50 Kg) were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred onto polyvinylidene diflouride membranes, and immunoblotted. The primary antibodies used were anti-caspase-3 (SigmaAldrich, St. Louis, MO), anti-caspase-9 (Stressgen Biotechnologies Corporation, Victoria, BC, Canada), anti-X-linked inhibitor of apoptosis protein (XIAP) (Cell Signaling Technology, Inc.), and anti-excitatory amino acid transporter 2 (EAAT2) antibodies (Chemicon International, Temecula, CA). After incubation of membranes with HRP-coupled Significantly larger number of motor neurons survived in the hrHGF-treated G93A Tg rats compared with vehicle-treated G93A Tg rats (6.7 T 1.6 vs 2.3 T 0.9; p = 0.002, n = 6 in each group) (C). secondary antibodies, proteins were visualized using ECL or ECL Plus Western Blotting Detection Reagents (Amersham Biosciences Inc., Piscataway, NJ) and a Fluorochem image analyzer (LAS-3000 mini; Fuji Photo Film Co., Tokyo, Japan).
Statistical Analysis
The Kaplan-Meier and log-rank test were used for statistical analyses of differences in onset and survival between groups. For statistical analyses of differences in body weight, footprint, motor neuron cell count, and Western blotting we used analysis of variance and post hoc tests. The data are reported as means T SD.
RESULTS
Measurement of the Levels of Rat HGF and c-Met Expression in Untreated Animals
Groups of 3 G93A Tg rats and non-Tg rats at 70, 100, and 130 days were used to measure the levels of rat HGF without any treatment. In the lumbar cords of untreated G93A Tg rats, the HGF concentrations increased with disease progression (Fig. 1A ). At 70 days the level of rat HGF in the lumbar cords of G93A Tg rats was 4.05 T 0.6 ng/ mg and was the same as that of non-Tg rats. Increases of 35% and 107% were observed in the rat HGF level at 100 and 130 days, respectively, compared with non-Tg rats.
In addition, we measured the levels of c-Met mRNA in the lumbar spinal cords of Tg rats relative to non-Tg rats by real-time quantitative PCR. In the lumbar cords of G93A Tg rats the level of c-Met mRNA expression was the same as that in non-Tg rats at 70 days. However, a 55% increase in the level of c-Met mRNA expression compared with that of non-Tg rats was observed at 100 days and the higher level of expression was retained at 130 days (Fig. 1B) .
Administration of hrHGF to 100-Day-Old G93A Tg Rats for 4 Weeks
To examine the efficacy of hrHGF on motor neurons in the spinal cords of Tg rats against onset of disease we administered 40 and 200 Kg of hrHGF or vehicle alone to 100-day-old G93A Tg rats for 4 weeks (n = 8 in each group).
Animals were killed at 130 days, and their lumbar spinal cords were examined. Because administration of hrHGF for more than 30 days may induce antibodies against hrHGF, we did not treat rats for longer than this period. We confirmed elevation of human HGF concentrations in the lumbar cords of hrHGF-treated rats using a specific sandwich immunoassay. The mean human HGF concentrations were 83.9 T 25.1, 15.6 T 5.4, and 0 ng/mg for rats treated with 200 Kg of hrHGF, 40 Kg of hrHGF, and vehicle, respectively (Fig. 2F) . The endogenous rat HGF concentration is 4 to 5 ng/mg at this age (Fig. 1A) . The human HGF concentration in the spinal cord of G93A Tg rats treated with 200 Kg of hrHGF FIGURE 4. Sections of the fifth lumbar anterior horn from G93A transgenic (Tg) rats treated with human recombinant hepatocyte growth factor (hrHGF) (A, C, E, G) or vehicle (B, D, F, H) for 2 weeks starting at 115 days were stained with hematoxylin and eosin (A, B) and antibodies to phosphorylated c-Met (C, D), activated caspase-3 (E, F), and activated caspase-9 (G, H). Scale bar = 50 Km. There were larger numbers of remaining large motor neurons in hrHGF-treated G93A Tg rats (6.7 T 1.6) (A) than in vehicle-treated G93A Tg rats (2.3 T 0.9) (B). Phosphorylated c-Met staining was more distinct in hrHGF-treated G93A Tg rats (C) than in vehicletreated G93A Tg rats (D). In contrast, activated caspase-3 staining was stronger in vehicle-treated G93A Tg rats (F) than in hrHGF-treated G93A Tg rats (E). Activated caspase-9 staining was detectable in vehicle-treated G93A Tg rats (H) compared with little reactivity in hrHGF-treated G93A Tg rats (G). (Fig. 2AYE) . hrHGF prevented motor neuron death in G93A Tg rats in a dose-dependent manner.
Administration of hrHGF to 115-Day-Old G93A Tg Rats for 4 Weeks
We next examined the therapeutic potential of HGF when administration was started at around the age of onset of paralysis. We administered 200 Kg of hrHGF or vehicle alone to 115-day-old G93A Tg rats for 4 weeks. There were no statistically significant differences (p = 0.6346) in onset between the groups (200 Kg of hrHGF, 126.8 T 13.1 days; vehicle, 126.3 T 13.8 days) (Fig. 3A, dotted lines) . In contrast, 200 Kg of hrHGF extended mean survival by 11 days compared with vehicle-treated G93A Tg rats (p = 0.0135) (Fig. 3A, solid lines) , although G93A Tg rats showed very rapid disease progression and died within 20 days of disease onset. The average periods from the onset to death were 16.9 T 8.17 and 27.5 T 11.1 days in vehicle (n = 8) and hrHGF (n = 8) groups, respectively. The latter represented an increase of 62.7% relative to vehicle-treated controls. Footprint analysis of stride length in 200 Kg of hrHGF-treated G93A Tg rats showed significant improvement compared with vehicle-treated G93A Tg rats at 118 days (p = 0.0424) (Fig. 3B) . Thus, despite the very rapid disease progression in this model and short treatment period of 4 weeks, hrHGF treatment improved motor performance and prolonged survival even with treatment beginning around the onset of paralysis.
Histologic evaluation of the lumbar spinal cord indicated that hrHGF treatment prevented the pathologic changes typical of Tg rats. Two weeks after commencement of administration at 129 days, vehicle-treated rats showed substantial loss of motor neurons (2.3 T 0.9) compared with hrHGF-treated rats (6.6 T 1.6) (Figs. 3C, 4A, B) . A significantly larger number of motor neurons survived in hrHGFtreated G93A Tg rats than in vehicle-treated G93A Tg rats (p = 0.002). Histologic evaluation of the lumbar spinal cord revealed much greater numbers of phosphorylated c-Metpositive cells (which were presumed to be motor neurons because of their large size, multipolar form, and localization in the anterior horn of the spinal cord) in hrHGF-treated G93A Tg rats compared with vehicle-treated G93A Tg rats at 2 weeks after the start of administration at 129 days (Fig. 4C, D) . These observations indicated that the administered hrHGF was used in the spinal cord in G93A Tg rats. Consistent with the observation that apoptosis is involved in the pathogenesis of ALS (29Y32), immunohistochemical analyses indicated large numbers of cells positive for activated caspase-3 and caspase-9 in vehicle-treated rats (Fig. 4F, H) , compared with little or no reactivity in hrHGF-treated rats (Fig. 4E, G) . To assess the mechanisms of suppression of caspase-3 and caspase-9 activation in hrHGF-treated rats, we next examined the level of XIAP by Western blotting, as XIAP inhibits activation of these procaspases and its levels are decreased in ALS mice (31) . Western blotting analysis revealed increased XIAP expression FIGURE 5. Caspase-3 and -9, glial fibrillary acidic protein (GFAP), excitatory amino acid transporter 2 (EAAT2), X-linked inhibitor of apoptosis protein (XIAP), and A-tubulin expression in the lumbar spinal cord. Western blotting of lumbar spinal cord lysates from G93A transgenic (Tg) rats treated with 100 Kg of human recombinant hepatocyte growth factor (hrHGF) or vehicle for 2 weeks from 115 days. Western blotting analysis revealed increased levels of EAAT2 and XIAP expression in the spinal cords of hrHGF-treated G93A Tg rats compared with vehicle-treated G93A Tg rats (XIAP, p = 0.0099; EAAT2, p = 0.0417; n = 4). On the other hand, activated caspase-3 and -9 expression levels were decreased in hrHGF-treated G93A Tg rats. There were significant differences in caspase-3 expression between hrHGF-and vehicletreated G93A Tg rats (pro-caspase-3, p = 0.0031; activated caspase-3, 0.0154; n = 4). GFAP expression was equivalent in both groups.
in the spinal cord of G93A Tg rats, and the increase in hrHGF-treated rats was only 60% of that in vehicle-treated G93A Tg rats. On the other hand, activated caspase-3 and 9 levels were decreased in hrHGF-treated G93A Tg rats (p = 0.0154 and p = 0.2364, 75% and 69% of vehicle-treated G93A Tg rats, respectively). These were all considered to be effects of HGF on motor neurons. Finally, we examined whether HGF improves the function of other cell types, such as astrocytes. There was a 60% increase in glial-specific glutamate transporter (EAAT2) in hrHGF-treated rats compared with vehicle-treated controls, although there was little difference in GFAP expression levels between the 2 groups (Fig. 5) .
DISCUSSION
In this study, we demonstrated dose-dependent effects of hrHGF on motor neurons in the G93A Tg rat model of ALS, with administration starting at 100 days. Furthermore, we showed that hrHGF retards disease progression in this animal model treated from 115 days at the time of disease onset. There have been many studies of possible treatments in a mouse model of ALS (33, 34) , but few agents have been shown to prolong survival with administration starting around disease onset (6Y12). In this study, recombinant hrHGF retarded disease development even with administration beginning around the age onset of paralysis. Here, we showed the therapeutic effects of intrathecal delivery of a neurotrophic factor as a protein, rather than a transgene, on ALS beginning at the onset of paralysis. The average survival period of hrHGF-treated rats was 62.7% longer than that of vehicle-treated controls, comparable with the improved survival obtained by viral delivery of insulin-like growth factor-1 (6). We defined the appearance of paralysis as disease onset, although this is not a sensitive indicator and appears later than the decrease in activity (10) . However, the appearance of paralysis is a clinically relevant marker of disease onset because it is closer to the state at which patients will be diagnosed with the disease.
We confirmed elevation of the human HGF concentration in the lumbar cords of hrHGF-treated G93A Tg rats using a specific sandwich immunoassay. Histologic evaluation of the lumbar spinal cord revealed greater numbers of phosphorylated c-Met-positive motor neurons in hrHGFtreated G93A Tg rats. This finding suggested that HGF receptors of motor neurons were activated well by administered hrHGF (35) . These observations indicated that the administered hrHGF penetrated into the spinal cord and was utilized in the motor neurons of spinal cord. Previous studies demonstrated that many trophic factors have protective effects on motor neurons. In human trials of neurotrophic factors, such as brain-derived neurotrophic factors, glial cell line-derived neurotrophic factor, and insulin-like growth factor-1, the delivery (accessibility) of the protein to the motor neurons and glia in the spinal cord has been argued to be essential. Our results confirmed that chronic intrathecal administration with implanted infusion pumps supplied appropriate therapeutic doses to spinal cord motor neurons.
The HGF concentrations in cerebrospinal fluid are increased in many neurologic disorders, including ALS (26) . In G93A Tg rats, the level of endogenous HGF in the spinal cord showed significantly greater elevation when the pathologic changes began in the spinal cord and increased with progression of the disease compared with the level of endogenous HGF in the spinal cord of non-Tg rats. After onset, the level of endogenous HGF almost doubled relative to that in non-Tg rats (Fig. 1A) . These results were compatible to observations in patients with sporadic as well as familial ALS (36, 37) . The level of c-met RNA expression in the lumbar cord of G93A rats increased to 155% of the normal level from before onset, and this elevated expression was retained after onset of disease (Fig. 1B) . Kato et al (36) demonstrated that autocrine and paracrine trophic support of the HGF-c-met system contributes to attenuation of the degeneration of residual spinal cord motor neurons in ALS, whereas disruption of the HGF-c-met system at an advanced stage of disease accelerates cellular degeneration (37) . Administration of hrHGF delayed the pathologic changes in G93A Tg rats. This effect of HGF may be due to replenishment of the relative insufficiency of HGF in G93A Tg rats in the present study.
Consistent with the findings that apoptosis is involved in ALS (29Y31), large numbers of cells immunopositive for activated caspase-3 and -9 were observed in vehicle-treated animals in contrast to little or no reactivity in hrHGF-treated rats. This result was verified by quantitative Western blotting analysis, which indicated that HGF could block caspase activation of apoptosis. Caspase-3 and -9 are the main factors involved in execution of the caspase cascade. The survivalprolonging effect of HGF may be explained by suppression of induction and activation of caspase-9, as this enzyme is involved in determining disease duration (31) . These observations suggest that the mechanism of the therapeutic effect of HGF in G93A Tg rats includes inhibition of the caspase cascade or of the cell death mechanism preceding the caspase cascade. In addition, EAAT2 and XIAP expression levels were increased in the hrHGF-treated group compared with vehicle-treated controls, indicating that HGF affected not only motor neurons via inhibition of the caspase cascade but also other cell types, such as astrocytes, which support motor neurons by maintaining or reinforcing internal cell protective functions, such as EAAT2 and XIAP.
Our results demonstrate pathologic improvements and retarded progression of ALS in G93A Tg rats by intrathecal administration of hrHGF from around the time of disease onset. Because HGF and c-Met are thought to be regulated in cases of not only familial but also sporadic ALS in a manner similar to the Tg mouse model of ALS (36) , our findings suggest the possibility of clinical use of HGF in both familial and sporadic ALS. The results indicating the efficiency of hrHGF administration even from the onset of paralysis should prompt further clinical trials in ALS.
